Specialties – Page 87

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications

By MedXY 09/10/2025

Phase 3 trials demonstrate that encapsulated cell therapy NT-501 significantly slows photoreceptor loss in MacTel, marking a promising disease-modifying approach with an acceptable safety profile.

Diabetes & Endocrinology Specialties Transplantation

Advancing Type 1 Diabetes Care: Stem Cell-Derived Islet Therapy with Zimislecel

By MedXY 09/10/2025

Zimislecel, an allogeneic stem cell-derived islet-cell therapy, demonstrates promising safety and efficacy for type 1 diabetes, restoring physiologic islet function and enabling insulin independence in a phase 1-2 trial.

Diabetes & Endocrinology Medical News Specialties

The Most Cost-Effective Exercise Discovered: Just 4 Minutes Daily Cuts Heart Disease Risk by 45%

By MedXY 09/09/2025

A new study reveals that short bursts of vigorous 'snack exercise' totaling as little as 3–4 minutes daily can significantly reduce cardiovascular disease risk, especially among women.

Cardiology Dentistry Family Medicine & Nutrition Specialties

Understanding Oral Cancer: Risks, Symptoms, Treatments, and Prevention

By MedXY 09/09/2025

Explore the causes, warning signs, treatment options, and preventive strategies for oral cancer, a malignant tumor commonly affecting adults aged 40 to 60. Early detection significantly improves survival outcomes.

Dentistry Family Medicine & Nutrition Specialties

Why Brushing Before Bedtime Matters More Than You Think: A Science-Backed Guide to Oral Health

By MedXY 09/09/2025

Skipping bedtime brushing causes more harm than skipping morning brushing. This article explains why, outlines signs of poor oral hygiene, and offers expert tips for effective dental care.

Family Medicine & Nutrition Specialties

Natural Drying or Blow-Drying? How to Best Care for Your Hair After Washing

By MedXY 09/09/2025

Explore the pros and cons of natural hair drying and blow-drying, understanding their effects on hair and scalp health, and learn expert tips to protect your hair while accommodating your lifestyle.

Medical News OB/GYN & Women's Health Oncology Specialties

Beyond Cervical Cancer: The Rising Threat of HPV-Linked Oropharyngeal Cancer in Men

By MedXY 09/09/2025

HPV-related oropharyngeal cancer incidence has surpassed cervical cancer, with men facing a 5-10 fold higher risk. Understanding this shift, symptoms, risks, and the critical role of HPV vaccination can transform prevention and early detection.

Clinical Updates news Oncology Specialties

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates Hematology-Oncology Specialties

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

By MedXY 09/09/2025

A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring the need for targeted therapeutic strategies.

Clinical Updates Hematology-Oncology news Specialties

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

Clinical Updates Hematology-Oncology Specialties Transplantation

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

By MedXY 09/09/2025

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.

Clinical Updates Hematology-Oncology Specialties Transplantation

Multisite Randomized Trial of Inpatient Palliative Care in Hematopoietic Stem Cell Transplantation: Enhancing Patient and Caregiver Outcomes

By MedXY 09/09/2025

Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.

$Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up$

Clinical Updates Hematology-Oncology news Specialties

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

By MedXY 09/09/2025

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Insights From the POSITIVE Trial

By MedXY 09/09/2025

The POSITIVE trial reveals that two thirds of women with early hormone receptor-positive breast cancer successfully breastfed post-treatment, without a significant increase in cancer recurrence risk, offering reassurance to women considering pregnancy and breastfeeding after breast cancer.

OB/GYN & Women's Health Oncology Specialties

ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges

By MedXY 09/09/2025

The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predictors.

$Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1$

Clinical Updates Hematology-Oncology news Specialties

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

By MedXY 09/09/2025

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a favorable safety profile.

Clinical Updates news Oncology Specialties

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Clinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

By MedXY 09/09/2025

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.

Clinical Updates Oncology Specialties

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY 09/08/2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Clinical Updates news Oncology Specialties

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.